Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

VTRS - Viatris Inc


IEX Last Trade
12.49
0.030   0.240%

Share volume: 109,262
Last Updated: Thu 26 Dec 2024 08:30:21 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) : 1.30%

PREVIOUS CLOSE
CHG
CHG%

$12.46
0.03
0.24%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
23%
Profitability 6%
Dept financing 43%
Liquidity 55%
Performance 27%
Company vs Stock growth
vs
Performance
5 Days
-0.72%
1 Month
-5.20%
3 Months
6.71%
6 Months
18.89%
1 Year
15.78%
2 Year
12.32%
Key data
Stock price
$12.49
P/E Ratio 
-22.30
DAY RANGE
$12.35 - $12.54
EPS 
-$0.54
52 WEEK RANGE
$10.18 - $13.62
52 WEEK CHANGE
$14.29
MARKET CAP 
14.418 B
YIELD 
3.89%
SHARES OUTSTANDING 
1.194 B
DIVIDEND
$0.12
EX-DIVIDEND DATE
08/23/2024
NEXT EARNINGS DATE
11/05/2024
BETA 
0.57
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$14,210,403
AVERAGE 30 VOLUME 
$9,436,829
Company detail
CEO: Michael Goettler
Region: US
Website: viatris.com
Employees: 37,000
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services

Viatris Inc. operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies.

Recent news